Fen EP Limited

Life Sciences
Sudden Cardiac Death prevention
Aim of funding: 
HMRC Advance Assurance received: 

Fen EP Limited


PEFA (‘paced electrogram fractionation analysis’) is a unique procedure and was invented by cardiologist Dr Richard Saumarez , initially when based at St Georges Hospital, London, and subsequently developed and tested at the University of Cambridge and Papworth Hospital.

The procedure that has been perfected effectively reduces the number of  implanted cardioverter-defibrillators (‘ICD’) resulting in significant and ongoing cost savings for hospitals and medical centres, in addition to reducing the number of people who are considered low risk having unnecessary surgery and an ICD.

An ICD is a small device placed in a patient’s chest or abdomen, used to address irregular heartbeat or mitigate the risk of sudden cardiac arrest. The device sends electrical pulses to the heart when it senses any abnormalities in heartbeat periodicity. The biggest difference between an ICD and a pacemaker is that an ICD continually monitors heart rhythm and can send low- or high-energy electrical pulses to correct an abnormal heart rhythm.

The Company is focused on the development of instrumentation for the prediction of sudden cardiac death (SCD).  


According to recent reports, the ICD implantation rate in the UK was 32,135 of which 10,176 (31%) were replacements. In Germany, the rate was 76,046 of which 25,349 (33%) were replacements. In France, the rate was 48,487 of which 16,162 (33%) were replacements. However, the largest market remains the US, in which the rate of implantation was 235,567 of which 101,042 (43%) were replacements.

Revenue from the global cardiac rhythm management market, consisting of pacemaker (PM), implantable cardioverter-defibrillator (ICD), cardiac resynchronisation pacemaker (CRT-P) and cardiac resynchronisation therapy defibrillator (CRT-D) devices, is forecast to increase at a compound annual growth rate of 4.6% from US$10.9bn in 2012 to more than US$15.7bn by 2020. 

Information on this webpage relates to and is provided by Deepbridge Advisers Limited.

The content of this webpage should not be construed as financial advice. Any decision to invest should be made only on the basis of the relevant documentation for each investment. Past performance is not necessarily a guide to future performance. The value of an investment may go down as well as up and investors may not get back the full amount invested. Investments in small unquoted companies carry an above-average level of risk. These investments are highly illiquid and as such, there may not be a readily available market to sell such an investment. Deepbridge Capital LLP, Deepbridge Advisers Limited and Enterprise Partners LLP (together "the Sponsors," or "Sponsor) do not provide specific individual advice on the suitability of investments with regard to a potential investor's individual circumstances, risk tolerance or investment objectives and investors should seek independent financial advice if they are in any doubt whether a product is suitable for them.